Conclusions: PTSD, diagnosed according to DSM-IV criteria, is more common in survivors of cancer than it is in the general population. Estimates of the occurrence of PTSD in patients with a history of cancer depend upon clinical and demographic factors, as well as upon study design.
INTRODUCTION
Psychological distress and morbidity may be triggered or exacerbated by a cancer diagnosis. Along with financial problems, role reversals, and the physical consequences of treatment (Arozullah et al., 2004; Emslie et al., 2009; Stein, Syrjala, & Andrykowski, 2008) , cancer survivors face a variety of psychological sequelae of their disease, including loneliness and fear of recurrence (Fox, Harper, Hyner, & Lyle, 1994 ; LeeJones, Humphris, Dixon & Hatcher, 1997). Although much attention has focused on depression and anxiety after cancer diagnoses, a recent systematic review found that cancer survivors have no increased risk of depression and only 1.27 times the relative risk of anxiety compared to control participants (Mitchell et al., 2013) .
Cancer may cause psychological morbidity in the form of posttraumatic stress disorder (PTSD). PTSD is said to arise from an inadequate cognitive processing of trauma memories (Brewin, 2007 numbing, and hyperarousal symptoms, such as an exaggerated startle response (APA, 1994) . A diagnosis of serious illness was listed as one potential traumatic stressor in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) (APA, 1994) . Cancer fits both of the DSM-IV criteria for a traumatic stressor; it is lifethreatening and may trigger "intense fear, horror, and helplessness" (APA, 1994) . Newer DSM-5 criteria focus on the medium and duration of the trauma while excluding any characterization of its subjective experience, but according to the DSM-5, a medical illness such as cancer is only considered a traumatic event when it is "sudden" and "catastrophic" (APA, 2013) . Furthermore, there have been a number of changes to the formulation of a PTSD diagnosis in DSM-5 that might impact on its applicability within a cancer setting; for instance, the three symptoms described in the DSM-IV have now been divided into four, including a new category of "negative cognitions."
Apart from this, there are a number of conceptual issues surrounding the inclusion of cancer within a traumatic stress framework.
As Kangas, Henry, and Bryant (2002) , Smith, Redd, Peyser, and Vogl (1999) , and Gurevich, Devins, and Rodin (2002) discuss, the cancer experience may involve multiple traumatic events over the course of diagnosis and treatment, some of which are complex and repeated.
Furthermore, cancer may be considered an "internal" threat, rather than an external threat from, for example, attackers or natural disasters (Green et al., 1998; Gurevich et al., 2002; Kangas et al., 2002) .
Whether an internal threat to one's health can function as a trauma is controversial. Gurevich et al. (2002) and Mehnert and Koch (2007) argue that some of the most distressing aspects of the cancer experience are those that involve uncertainty or a fear of potential death in the future, rather than discrete external traumatic events taking place in the past; nevertheless, Mehnert et al. (2007) also found that diagnosis itself, a discrete event, is often perceived as traumatic.
Furthermore, some of the symptoms of PTSD, such as a loss of concentration or insomnia, may be attributable to cancer or its treatment (Gurevich et al., 2002; Kangas et al., 2002) . As Smith et al. (1999) discuss, cancer also differs from other types of traumatic stressors in that its "threat," or risk of pain, death, or injury, varies considerably from case to case. Rustad, David, and Currier (2012) have recently highlighted the concern that cancer itself causes generalized distress in the forms of sadness, anger, and worry and that these symptoms are conflated with PTSD (Green et al., 1998) . Another concern is that factor structures of PTSD scales in cancer populations have not always conformed to the three-factor structure of PTSD (Rustad et al., 2012) . One study found numbing and avoidance as separate symptoms, inconsistent with DSM-IV symptomatology, and weak factor loadings (Shelby, Golden-Kreutz, & Andersen, 2005) . However, other studies from noncancer settings have also found a four-factor structure for PTSD scales (e.g., Palmieri, Weathers, Difede, & King 2007; Reddy, Anderson, Liebschutz, & Stein, 2013) . Therefore, there is significant debate as to whether cancer conforms to the traditional picture of a trauma causing PTSD.
In the literature, the proportion of cancer survivors with PTSD has varied widely, from 36 to 45% of ovarian cancer survivors (Gonçalves, Jayson, & Tarrier, 2011) to 6% of breast cancer survivors (Andrykowski, Cordova, Studts, & Miller, 1998) . found that time since the end of treatment, stage of cancer at diagnosis, and psychosocial factors such as social support predict levels of PTSD.
Other studies have since confirmed that sources of this variation may include clinical factors such as time since diagnosis (Gold et al., 2012) and stage of disease (Mundy, 2002) or demographic factors such as age (Kangas, Tate, Williams, & Smee, 2012) and gender (Voigtmann et al., 2010) .
Family members or caregivers of cancer survivors may also experience negative psychosocial outcomes, such as anxiety and depression (Given et al., 2004; Park et al., 2013) . Family caregivers of cancer patients have a poorer quality of life than cancer patients themselves (Mellon, Northouse, Weiss, 2006) . Ell, Nishimoto, Mantell, and Hamovitch (1988) found that individuals close to cancer survivors were still experiencing distress related to the cancer a year after their family member's diagnosis. Smith et al. (1999) found that parents of cancer survivors have a greater risk of PTSD than their children. These studies are concordant with a systemic approach to illness, which assumes that the cancer experience takes place within a social system of delicate dynamics and interrelationships (Rolland, 2005) . In line with this literature, we decided to include studies sampling family members and caregivers of cancer survivors in our review.
This review contributes to the debate about whether cancer can function as a traumatic stressor by identifying factors significantly affecting the reported proportion of a postcancer diagnosis sample with PTSD, expressed as a percentage. We also calculate the relative likelihood of PTSD in cancer survivors compared to controls without cancer. We assessed current PTSD, rather than lifetime PTSD, as studies investigating the latter were uncommon. This review includes studies applying DSM-IV or International Classification of Diseases (ICD) version 10 criteria for PTSD to adult cancer survivors at any stage of disease, from 1 month after diagnosis to many years after treatment has ended. DSM-IV and ICD-10 criteria for PTSD are closely related, including the same three symptom clusters, although the ICD-10 criteria require the traumatic event to be likely to cause "pervasive distress in almost anyone" (World Health Organization, 1994) while DSM-IV criteria require "fear, horror, and helplessness" (APA, 1994; US Department of Veterans Affairs National Center for PTSD, 2015). We have applied "Preferred reporting items for systematic reviews and metaanalyses" (PRISMA) guidelines (Liberati et al., 2009 ) and the "Metaanalysis of observational studies in epidemiology" (MOOSE) guidelines (Stroup et al., 2000) .
METHODS

Literature search strategies
The first stage of the literature review process was to query three Figure 1 . Papers were assessed for eligibility using the inclusion criteria in Table 2 .
Quality assessment
We undertook quality assessment of included papers using Loney et al.'s (2000) criteria for the assessment of epidemiological studies. This eight-item checklist assesses criteria relating to the selection of the sample, the measurement of the outcome, and the description of the results. As most of the studies identified for this review were retrospective or cross-sectional cohort studies, none met all eight criteria. Quality scores are shown in the quality criteria table,
Supporting Information 3. No study adjusted for known risk factors for PTSD, such as age or gender (Kangas et al., 2012; Voigtmann et al., 2010) .
In addition to this formal quality assessment, we focused on potential sources of bias in estimates of PTSD proportion; for instance, we 6. Studies written in the English language excluded papers that sampled from support groups and other settings for which the proportion of PTSD would be exaggerated, since seeking help is associated with greater severity of mental health problems (Bebbington et al.; Oliver, Pearson, Coe, & Gunnell, 2005) . Twelve papers were excluded based on this criterion. These papers sampled from among participants prescreened for high or low PTSD or depression scores; those identified by clinicians as having high levels of distress; those referred to or seeking counseling, psychology, or support services; and groups of participants with known psychiatric illness.
TA B L E 2 Inclusion and exclusion criteria for papers
Data extraction
Information extracted from studies meeting inclusion criteria included number of people with PTSD, sample size, PTSD measurement instrument, type of cancer, type of treatment, stage of cancer, mean time since diagnosis in months, country, gender, mean age of sample, whether the study was peer-reviewed or not, reliability of PTSD instrument, whether the sample included survivors or family members/caregivers, ethnicity, prior trauma, whether the PTSD was explicitly linked to cancer, or whether "posttraumatic stress" or any variant was included in the title or abstract of the paper. This list of variables was derived from previously identified risk factors (Gurevich et al., 2002) . For papers reporting estimates of PTSD in cancer survivors compared to noncancer controls, we also extracted the number of people with PTSD in the noncancer group and the size of this group.
When only abstracts were available, we contacted authors for further information and extracted all information possible from abstracts.
Authors were contacted for missing data if the papers did not report the number of people with PTSD. For longitudinal studies, we included only the latest data point available for all papers in order to take advantage of the longer latencies between diagnosis and PTSD assessment. This also allowed us to avoid double-sampling participants. If papers reported two methods of assessing PTSD, we included only the results from clinical interviews rather than self-report measures. Where authors reported time since the end of treatment, we added 6 months to derive an approximation of the time since diagnosis. Where medians rather than means were given, the data were considered missing.
Statistical procedures
We conducted random effects meta-analysis using Comprehensive Meta-Analysis 2.0 (Englewood, NJ, 2005) and Stata version 14.1 (StataCorp 4905 Lakeway Dr College Station, TX 7784). We used random effects rather than fixed effects because, in this case, it was reasonable to assume that the proportion of survivors with PTSD would not be uniform across all studies. We used the DerSimonian and Laird (1986) estimator for between-study variance. We calculated I 2 to determine the amount of heterogeneity (Higgins, Thompson, Deeks, & Altman, 2003) . For studies comparing cancer survivors to controls with no cases of PTSD in the control group, 0.25 was added to the denominator of the odds ratio to avoid a denominator of 0. All subgroup analyses were planned according to our protocol.
Factors affecting proportion of PTSD
Since the log proportion effect sizes represent single values, and not a comparison of values, investigation of variables influencing effect sizes would not appropriately be called "moderator analysis." However, we sometimes refer to it as such because this is the normal usage in meta-analyses. We conducted mixed-effects moderator analysis and "method of moments" (random effects) meta-regression to determine factors affecting the proportion of people with PTSD in a sample. Potential "moderators" included PTSD assessment tool (selfreport or clinical interview), type of cancer, type of treatment, stage of disease, time since diagnosis, global region, gender of sample, mean age of sample, whether the study was peer-reviewed or not, and the relationship of participants to the survivor (in samples of family members).
In response to literature asserting that self-report measures overinflate estimates of PTSD, we extracted information about type of PTSD measurement instrument and conducted moderator analyses to identify differences between measurement instruments in terms of PTSD proportion.
Reliability analysis
Reliability analysis was conducted both for study selection and data extraction. A second coder was asked to apply inclusion criteria to 10% of screened papers and determine whether they were eligible for this study; agreement was 93.8%. The two discrepancies were due to one of the coders missing information from the articles. A second coder was also asked to extract data from 10% of all studies included in the analysis. Of 108 items extracted, the coders agreed on 102 (94.4%) of items. Four of these discrepancies were due to the second coder missing information in the papers.
RESULTS
Description of studies
We identified 120 samples from 110 studies meeting inclusion criteria.
These studies included 16,755 participants, 1,812 of whom were diagnosed with PTSD according to individual study procedures for assessing PTSD, equivalent to an overall absolute proportion of 10.8%. Proportion of the sample with PTSD ranged from 0% to nearly 52%. Hematological, breast, prostate, colorectal, gynecological, brain, and head and neck cancers were represented. The majority of studies were conducted in North America. The authors of an additional 70 papers were contacted for missing data, but were either unable to provide data or did not respond to our request for missing data. A table of Publication bias was assessed using a plot of the observed PTSD proportion and the standard error of the estimate, as shown in 
Summary odds ratio
Of the 110 studies meeting eligibility criteria, 11 studies (12 samples) included a comparison group. We used random effects meta-analysis on this subset of 12 samples to calculate log odds ratios for PTSD for cancer survivors compared with controls who had no history of cancer.
The summary odds ratio was 1.66 (95% CI: 1.09-2.53). The Q test for heterogeneity was not significant; I 2 was 17.2%, indicating that relatively little variability between studies was attributable to heterogeneity. A forest plot illustrating effect sizes for each study and CIs can be found in Figure 4 . Odd ratios comparing occurrence of PTSD in cancer survivors compared to noncancer controls are generally larger than 1, indicating a higher likelihood of PTSD among cancer survivors.
In addition, we calculated the rate difference between noncancer controls and cancer survivors. The summary rate difference was 6.2% (95% CI: 1.6-10.8%), although analyses of bias, as described in Supporting Information 2, indicate that this estimate of difference may be inflated. A forest plot of the rate differences can be found in Figure 5 . A funnel plot demonstrating publication bias affecting these 12 comparison studies is shown in Figure 6 .
Factors affecting reported proportion of sample with PTSD
The above odds ratio reflects the relative likelihood of PTSD among cancer survivors compared to controls without a history of cancer. We also conducted analyses to determine the factors affecting the raw proportion of cancer survivors with PTSD within each sample. The following analyses are based on all studies that reported sufficient information on these variables. Since not all studies reported on all potential factors, the numbers included in each separate analysis may differ.
Measurement instrument
Eighty-two studies reported the proportion of PTSD as assessed by self-report measures and 31 assessed this figure through clinical interviews. Type of measurement instrument (clinical interview compared to self-report measure) had a significant effect on proportion of cancer survivors reporting PTSD (Q(1) = 24.8, P < .001). The percentage of people with PTSD assessed using clinical interviews was 4.0% (95% CI:
2.6-6.2%), while the percentage of people with PTSD assessed using self-report measures was 12.8% (95% CI: 10.8-15.0%).
Type of cancer
We also performed moderator analysis to determine whether type of cancer significantly influenced PTSD proportion. Moderator analysis indicated that there was a significant difference in terms of PTSD proportion across cancer types (Q(6) = 16.2, P = .013). 
Type of treatment
Moderator analysis indicated that there was a significant difference in terms of PTSD proportion across types of treatment (Q(3) = 13.3, P = .004). Table 4 , below, shows the summary proportion estimate for each type of treatment.
Geographic region
There was a significant difference in terms of PTSD proportion depending on the region where the data were collected (Q(3) = 68.9, P < .001). Table 5 , below, shows the summary proportion estimate for each geographic area.
Whether "posttraumatic stress" was in the title or abstract
We extracted data regarding whether "posttraumatic stress," PTSD, or any other variant of the term was in the title or abstract of the paper. Summary proportions of the sample with PTSD were significantly higher among those papers that did contain these terms in the title (Q(1) = 17.8, P < .001). Papers containing these terms in the title or abstract reported a proportion of PTSD of 12.2% (95% CI: 10.4-14.2) compared to studies that did not contain these words in the title or abstract, which reported a summary proportion of 2.8% (95% CI: 1.4-5.5).
F I G U R E 2
Proportions with PTSD and confidence intervals from 120 included studies, both comparative and noncomparative.
F I G U R E 3
A plot of standard error by proportion with PTSD, demonstrating publication bias in 120 samples, both comparative and noncomparative.
F I G U R E 4
Forest plot illustrating odds ratios, confidence intervals, and overall summary odds ratio representing the likelihood of PTSD after cancer diagnosis compared to noncancer controls.
Prior trauma
One hundred fourteen studies reported estimates of PTSD among samples that had not experienced a prior trauma, and six papers reported estimates of PTSD among cancer survivors who had experienced a prior trauma. PTSD estimates were significantly higher among the samples who had experienced a prior trauma (Q(1) = 6.1, P = .014).
Proportion with PTSD of the samples of survivors who had experienced a trauma prior to cancer was 19.4% (95% CI: 11.7-30.4). Among F I G U R E 5 Forest plot illustrating rate differences, confidence intervals, and overall summary rate difference, comparing cancer survivors to controls without cancer.
the samples who had not experienced a prior trauma, the summary proportion of PTSD was 9.9% (95% CI: 8.4-11.6).
Age
Mixed effects "method of moments" meta-regression demonstrated that the mean age of the sample was significantly related to log proportion with PTSD. Among papers reporting higher mean sample ages, proportion of sample with PTSD was lower. The slope of this relationship was calculated from raw, rather than logit, proportions. The slope indicated that, for each additional year increase in the mean age of a group, PTSD estimates would be predicted to decrease by 0.3%.
Time since diagnosis
Mixed effects meta-regression also demonstrated that time since diagnosis was negatively related to log proportion. Among papers that reported longer latencies between diagnosis and data collection, PTSD proportion was lower. As above, the slope of this relationship was calculated from raw proportions. The slope indicated that, for each additional year after diagnosis, PTSD percentage within a sample would decrease by 0.5%.
Factors that did not influence proportion of PTSD
No other variables significantly influenced proportion of the sample with PTSD. This includes stage, gender of sample (where the gender was entirely male or female), and whether or not the study was reported in a peer-reviewed journal. Family members/caregivers of relatives with cancer survivors did not differ from cancer survivors themselves in terms of the proportion of the sample with PTSD. Forty-nine studies specifically assessed PTSD related to cancer, and these did not differ significantly in terms of proportion with PTSD from studies that did not explicitly link PTSD to the cancer experience.
DISCUSSION
This systematic review and meta-analysis assessed the relative likelihood of PTSD among cancer survivors compared to controls and the factors influencing the proportion of cancer survivors with PTSD.
Among the 12 comparative studies we found, cancer survivors seem to have 1.66 times the odds of PTSD compared to controls who have not had cancer. In many of these studies, control participants were potentially traumatized as well, with some having nonmalignant disease (e.g., Voigtmann et al., 2010) However, it is also relevant to note that cancer survivors may still meet criteria for "adjustment disorder." Akechi et al. (2004) have shown that the prevalence of adjustment disorder among cancer survivors exceeds that of PTSD; Hund et al. (2016) estimate this prevalence at 12.4%. Therefore, it is a matter of ongoing controversy whether the category of adjustment disorder, rather than PTSD, better describes cancer survivors' experiences after their disease.
Our results must be interpreted in light of the broader range of changes made to the PTSD diagnosis within DSM-5 (APA, 2013).
According to DSM-5, medical illness no longer counts as a traumatic event, and the subjective criteria of "fear, horror, and helplessness" are no longer necessary. However, DSM-5 PTSD also requires a different constellation of symptoms; for instance, while DSM-IV required avoidance and emotional numbing symptoms, DSM-5 requires avoidance symptoms as separate from a new category of symptoms referred to as "negative cognitions." Kangas (2013) discusses the implications of these changes for future diagnoses of PTSD among a cancer population, showing that the DSM-5 criteria for PTSD may not readily apply to cancer survivors, as many of their negative cognitions are related to future-oriented worries and concerns rather than memories of the past. Therefore, the prevalence of DSM-5 PTSD among cancer survivors is uncertain.
It is important to mention that our meta-analysis compared the proportion of people with PTSD within varying postcancer samples across different factors, but these proportions do not easily translate into overall prevalence figures. To determine the overall prevalence of PTSD among cancer survivors, we would need to have synthesized data from across large, population-based epidemiological studies. Unfortunately, few such studies exist. However, many studies reported a raw proportion of the total sample with PTSD; these are the figures that we have synthesized in our review and the types of papers that we included. Given the variations in quality and representativeness of these studies, this paper is a step toward understanding the factors that influence these raw proportions of PTSD among diverse cancer samples, but it cannot establish an overall figure for the prevalence, at the population level, of PTSD after a diagnosis of cancer.
Our study had several limitations. First of all, a high number of potentially eligible studies were excluded because of missing data. This was partly due to the fact that many studies were nearly 20 years old, and in many cases data were not retained for such a long period.
Furthermore, this study provides a synthesis of proportion of cancer survivors with PTSD, since that was the measure of PTSD most frequently reported. As a result, the studies included in this review assessed current PTSD rather than lifetime PTSD. We found very few studies assessing lifetime risk of cancer-related PTSD. Therefore, the above results may be taken as an indication of how many cancer survivors are currently living with PTSD, but it does not tell us how many cancer survivors have ever had PTSD or how many cancer survivors are likely to experience PTSD at any time after diagnosis. Furthermore, few studies assessed the impact of traumas in the period intervening between diagnosis and the measurement of PTSD symptoms, although our finding that proportion with PTSD decreases as time since diagnosis increases suggests that participants did not experience many traumas in this period.
Relatedly, most of the studies included in this review were crosssectional; few studies were prospective or longitudinal. This is important because cross-sectional studies such as those included in our review cannot give likely timeframes for the development of PTSD nor, as described by Kangas et al. (2002) , can they illuminate its potential course. Our results, in part, reflect a lack of prospectively designed studies. Therefore, our results reflect the likelihood of having PTSD at specific points after diagnosis based on different variables, but not the cumulative likelihood of developing PTSD after diagnosis. In addition, although many studies linked posttraumatic stress directly to the cancer experience, for some others, it was not clear whether PTSD was present before the cancer diagnosis. This may be seen as a limitation of the study, because this implies that some cases of PTSD might have been present before a cancer diagnosis. However, the proportion of the sample with PTSD did not seem to differ among papers indexing PTSD directly to the cancer experience and papers for which this was unclear.
We believe that this is because many studies in the latter category did, in fact, index PTSD to the cancer experience, although this linkage was not formally reported.
There may be interactions between variables considered separately in this analysis. For example, as above, three papers reported very high estimates of PTSD after chemotherapy. However, these studies used self-report measures, and a fourth study on PTSD after chemotherapy as assessed by clinical interview reported a much lower figure. It is difficult to determine whether the higher figures are attributable to chemotherapy or to the use of self-report measures. From this collection of cross-sectional studies, it is difficult to determine whether or not such measurement error has occurred in this analysis. Related to this point, it is also the case that there were often unequal numbers of studies reporting on different levels of moderator variables. This is a common occurrence in meta-analysis, as papers occur in varying frequency in the literature. However, in our study this may constitute a limitation, as it is unclear whether, for instance, the three studies reporting on PTSD after radiotherapy are representative.
We expected There is debate as to whether self-report measures are sufficiently robust to be used as diagnostic tools for PTSD. On one hand, self-report scales such as the Posttraumatic Stress Checklist (PCL) have shown acceptable functionality as screening tools for PTSD (Blanchard, Jones-Alexander, Buckley, & Forneris, 1996; Brewin, 2005) . However, more recently, evidence has emerged that self-report measures overestimate the proportion of people reporting PTSD (Einsle, Kraft, & Köllner, 2012) . In response, some researchers (e.g., Eisenberg et al., 2015; Hahn et al., 2015) have used self-report measures to assess posttraumatic stress symptomatology or generalized cancer-related distress, without using cut-offs for a PTSD diagnosis.
Our results indicate that participants who use self-report measures are roughly three times more likely to meet criteria for PTSD than are those assessed using diagnostic interviews. This supports the view that self-report measures, while potentially useful indicators of symptomatology, should be used with caution as diagnostic tools, particularly in patients treated for cancer.
Older participants were less likely to have PTSD, which is consistent with literature on older age and posttraumatic stress (Magruder et al., 2004) . Female participants did not have a higher proportion of PTSD, in contrast to previous reports (Breslau, 2002) . This may have to do with the fact that few studies reported separate proportion figures for each gender, so we were unable to detect such differences. Additionally, some have argued that symptoms of PTSD persist over time, and that they are not necessarily a part of "natural" recovery (Brewin, 2007) . Our results suggest that the proportion of a sample with PTSD may be lower in studies sampling further from diagnosis, although the proportion does not fall to zero over time. Finally, groups of participants who had had a prior trauma were more likely to report PTSD, as has been reported previously in the literature (Breslau, Chilcoat, Kessler, & Davis, 1999) .
We were unable to explore the effect of ethnicity upon cancerassociated PTSD as very few studies reported figures separately for each ethnic group. Anecdotally, we note that many studies reporting the ethnic breakdown of their samples reported percentages of Caucasian participants in excess of 80%. A recent study (Vin-Raviv et al., 2013) has indicated that ethnicity may be an important risk factor for the development of cancer-related PTSD, but this study was ineligible for our review because it used the Impact of Events Scale, a measure that does not include all symptoms of PTSD. Given evidence that marginalized groups may be disproportionately affected by trauma (Muldoon & Lowe, 2012) , we believe this topic requires further empirical investigation.
Estimates of the proportion of a sample with PTSD depended on several factors related to the context within which studies were performed and published. Studies conducted in Asia reported lower levels of PTSD, while studies conducted in the Middle East (mostly Israel) reported higher levels of PTSD. These differences may be attributable to cultural differences or to differing diagnostic practices; it is not clear from our study what the source of these differences is. Estimates of the proportion of PTSD were not significantly different between published studies that had been peer reviewed (n = 99) and those that had not (n = 21). However, studies containing the words "posttraumatic stress"
were significantly more likely to report a higher proportion of PTSD, a possible example of confirmation bias.
Relatives and caregivers of cancer survivors had PTSD in similar proportions to cancer survivors themselves. This finding is concordant with other studies that have shown that relatives and caregivers are equally, if not more, affected by the cancer experience (e.g., Grunfeld, 2004 ). This finding is also interesting in light of the fact that the etiology of PTSD may be different for cancer survivors than it is for their significant others. According to the DSM-IV (APA, 1994), an event triggering a PTSD diagnosis involves "a threat to the physical integrity of self or others." In the case of family members of cancer survivors, their PTSD is associated with traumas that are vicariously, rather than directly, experienced. Despite the difference in triggers between cancer survivors and their family members, PTSD proportions did not seem to differ between these two groups. This strengthens the argument, informed by a systemic approach to illness (Rolland, 2005) whether researchers in this area must shift focus onto the category of "adjustment disorder" rather than PTSD.
CONCLUSION
Cancer survivors are at increased risk of PTSD, as defined according to the DSM-IV criteria for PTSD. Synthesis of the 12 eligible comparison studies shows that cancer survivors have 1.66 times the odds of PTSD compared to controls with no history of cancer. The rate difference between the two groups is 6.2%. There is little heterogeneity among the papers contributing to the estimate of this odds ratio. This finding is noteworthy given the controversy surrounding the inclusion of cancer within a traumatic stress framework and the fact that cancer is no longer officially considered a traumatic event according to the DSM- 
